Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1H | O95180 | 5/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.40 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.39 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.39 |
| ▸ | POLQ | O75417 | 1/20 | 0.38 |
| ▸ | CCNC | P24863 | 2/20 | 0.38 |
| ▸ | CDK8 | P49336 | 2/20 | 0.38 |
| ▸ | AR | P10275 | 3/20 | 0.38 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.38 |
| ▸ | PGR | P06401 | 1/20 | 0.38 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.37 |
| ▸ | SMO | Q99835 | 1/20 | 0.36 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1013824 | 0.91 | TGFBR1 (0.41) | NOTUMNR3C1POLQCCNCCDK8 | |
| SCHEMBL3882497 | 0.88 | CACNA1H (0.43) | CACNA1HNOTUMFFAR4NR3C1POLQ | |
| SCHEMBL1013067 | 0.86 | CCNC (0.44) | CACNA1HNOTUMPOLQCCNCCDK8 | |
| SCHEMBL1016472 | 0.82 | CCNC (0.45) | CACNA1HNOTUMPOLQCCNCCDK8 | |
| SCHEMBL1012899 | 0.80 | CCNC (0.44) | NOTUMPOLQCCNCCDK8AR | |
| SCHEMBL3688007 | 0.80 | AR (0.47) | NOTUMFFAR4CCNCCDK8AR | |
| SCHEMBL3882096 | 0.79 | FFAR4 (0.49) | CACNA1HFFAR4NR3C1ARFFAR1 | |
| SCHEMBL1012795 | 0.79 | CCNC (0.44) | CACNA1HNOTUMPOLQCCNCCDK8 | |
| SCHEMBL1016963 | 0.78 | CCNC (0.41) | NOTUMPOLQCCNCCDK8AR | |
| SCHEMBL1014398 | 0.78 | CCNC (0.43) | CACNA1HNOTUMFFAR4POLQCCNC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8772327-B2 | Phenylpropionic acid derivative and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2014-07-08 | — | — | US | disclosed |
| US-20130131134-A1 | PHENYLPROPIONIC ACID DERIVATIVE AND USE THEREOF | MORITA KOHEI (JP) | 2013-05-23 | — | — | US | disclosed |
| US-8334314-B2 | Phenylpropionic acid derivative and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2012-12-18 | — | — | US | disclosed |
| EP-2272832-A1 | PHENYLPROPIONIC ACID DERIVATIVE AND USE THEREOF | Asahi Kasei Pharma Corporation (JP) | 2011-01-12 | — | — | EP | disclosed |
| US-20100093819-A1 | PHENYLPROPIONIC ACID DERIVATIVE AND USE THEREOF | ASAHI KASEI PHARMA CORPORATION (JP) | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131134-A1 | PHENYLPROPIONIC ACID DERIVATIVE AND USE THEREOF | PLA2G12A, PLA2G4A, PLA2G4B | CACNA1H 1324/4885NOTUM 1047/4885FFAR4 79/4885 |
| US-20100093819-A1 | PHENYLPROPIONIC ACID DERIVATIVE AND USE THEREOF | PLA2G12A, PLA2G4A, PLA2G4B | CACNA1H 1324/4885NOTUM 1047/4885FFAR4 79/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.